$CMMB

Best Momentum Stocks to Buy for Oct. 23

PARR, CMMB and GES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 23, 2025.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Oct 23, 2025, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Best Momentum Stocks to Buy for Oct. 23 — source image
Decision brief

The 30-second read

$CMMBNeutralMed
01

Why it matters

While the stocks are identified as momentum leaders, their neutral to slightly bullish sentiments indicate cautious optimism rather than strong buy signals.

02

Market read

The stocks have moderate relevance for momentum traders seeking short-term gains, but are not major market movers.

03

What to watch

Broader macroeconomic factors, upcoming earnings reports, or sector-specific news could significantly alter these stocks' trajectories, which are not accounted for in this analysis.

Timing: Short to medium-term

Background

The article highlights stocks with strong recent momentum, ranking them as potential buy candidates for October 2025.

Company-level read

Ticker impact

$CMMBNeutralMedium confidence
Context

Moderately relevant due to a neutral sentiment score and a relevance score of approximately 68%.

Expected impact

Minimal short-term price movement expected; potential for gradual appreciation if broader momentum persists.

Evidence & confidence

The neutral sentiment and moderate relevance suggest limited immediate impact, but momentum characteristics warrant monitoring.

$PARRBullishMedium confidence
Context

Moderately relevant with a somewhat-bullish sentiment and relevance score of approximately 68%.

Expected impact

Potential for short-term price appreciation of 3-5% if momentum sustains.

Evidence & confidence

The somewhat-bullish sentiment and relevance support cautious optimism, especially for swing traders.

Market effects

Potential positive influence on Life Sciences and Manufacturing sectors due to momentum in related stocks.

Limited regional impact; primarily affecting domestic markets where these stocks are listed.

Minimal; these stocks are not major global market movers.

Counterpoint

The neutral sentiment and moderate relevance suggest that the stocks may not sustain current momentum; a reversal or consolidation could occur, leading to limited gains or declines.

Key entities

  • Zacks Equity Research

    Provider of stock research and analysis.

Related articles

$PARRMed

Will Tight Product Inventories Boost PARR's Refining Outlook?

Par Pacific Holdings (PARR) reported strong Q2 results due to favorable refining conditions, with a refining index of $31.34/barrel in July. The company expects tight product inventories to support refining margins. PARR's shares rose 103.8% in six months, trading at a lower EV/EBITDA than industry average. PBF Energy (PBF) and Valero Energy (VLO) are also positioned to benefit from current market conditions.

$PARRHighAI 9/10

Par Pacific (PARR) Q2 2026 Earnings Call Transcript

Par Pacific Holdings (PARR) reported Q2 2026 adjusted EBITDA of $571 million, up from $91.5 million in Q1, and adjusted net income of $499 million ($10.10/share). Management cited a $33/bbl combined market index and record Washington throughput of 41,200 bpd. The company reduced term debt by 20%+, cut net debt by $220 million+, and ended June 30 with $1.4 billion liquidity.

$PARRMed

Par Pacific Q2 Earnings Call Highlights

Par Pacific (NYSE:PARR) reported Q2 refinery and retail updates on an earnings call. Hawaii capture was 124% (net price-lag benefit about $77M). Tacoma processed 41,200 bpd at 98.1% utilization. Q3 guidance: Hawaii conventional 59,000-65,000 bpd, renewables 1,500-2,000 bpd; consolidated refining index $31.34/bbl. Cash from ops was $614M; net debt fell over $220M after $500M notes.

$PARRMed

PAR PACIFIC HOLDINGS, INC. (PARR): Results of Operations and Financial Condition

PAR PACIFIC HOLDINGS, INC. (PARR) filed an SEC Form 8-K — Results of Operations and Financial Condition. NEWS RELEASE PAR PACIFIC HOLDINGS REPORTS SECOND QUARTER 2026 RESULTS HOUSTON, August 4, 2026 - Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific” or the “Company”) today reported its financial results for the quarter ended June 30, 2026. • Net income attributable to Par Paci

$CMMBMedAI 8/10

Chemomab Therapeutics, Scipher Medicine Announce Merger Agreement, Stock Down In Pre-Market

Chemomab Therapeutics (CMMB) and Scipher Medicine agreed to merge, forming a Nasdaq-listed company trading as SCIP. The combined firm will advance nebokitug, an anti-CCL24 antibody, into a Phase 2 rheumatoid arthritis trial. Chemomab holders expected to own ~32% and Scipher ~68%, with contingent value rights. About $30M new funding; cash expected to fund through H2 2028. Deal expected to close Q4 2026; CMMB down to $2.39 pre-market.